Join Now

Utah Life Sciences News & Events

Innovative Med Tech Startup Xenter Announces Company Launch

April 16, 2021

Xenter has announced its formal launch in Salt Lake City. Founded in 2020 by seasoned life sciences entrepreneur Richard J. Linder, Xenter is innovating new wireless technologies and techniques for the treatment of heart and vascular disease. The company’s next-generation devices will integrate functions that formerly required multiple costly devices.

“We are bringing the world’s leading medical experts to Xenter in order to drive dynamic changes to interventional medicine, therapeutic drug development, and digital health technology globally,” said Richard J. Linder, founder, chairman and CEO of Xenter, Inc.

“This is exciting news,” said Kelvyn Cullimore, president and CEO. “Xenter and our BioHive community are innovators at heart, working to make a difference in patients’ lives.”

The Xenter platform will enable novel therapeutic drug research by combining Physical Intelligence™ data with historical health data and other relevant information provided by patients and other patient-authorized sources.

According to Linder, Xenter is developing radically innovative medical devices using Xenter’s sensors and signals technology that enables wireless physiologic data collection, wireless intravascular imaging, and software technologies for the treatment of heart and vascular disease. The company has assembled an all-star cast of medical scientists, cellular biologists, pharmacologists, electrical engineers, mechanical engineers, researchers, practitioners and some of the world’s most experienced and accomplished entrepreneurs and industry veterans, which will be announced shortly.

Xenter’s next-generation devices will integrate functions that formerly required multiple costly devices and drive a generational improvement in the efficiency and effectiveness of interventional medicine.

On an ongoing basis, vast amounts of data are collected from clinical trials and real-world experience with drugs and devices from MedTech, Pharma and Biotech. Previously, these data have been focused on specific clinical studies. Xenter will capitalize on this opportunity to harness larger amounts of information in its Physical Intelligence™ data sets for improved target drug discovery and design, clinical trial strategy, patient recruitment, trial site selection, clinical trial monitoring and overall decision making.

“The future of medicine lies at the crossroads of regenerative medicine, new data collection techniques to facilitate targeted therapeutic drug development, combination devices that utilize novel therapeutics delivered by new devices, and new sensors and signals technologies utilized in hospitals and outpatient care settings, ” said Linder.

Linder is a seasoned entrepreneur who has founded or co-founded multiple successful medical device companies and held leadership and CEO roles in several leading biotechnology organizations. Linder has also been instrumental in advancing the life sciences industry. He is the founder and chairman emeritus of BioUtah, Utah’s independent life sciences association representing the state’s medical device, drug discovery and diagnostic companies. His additional industry background is available here.

The team’s first innovation, which Xenter will announce shortly, is a medical device that will revolutionize the field of interventional medicine by producing valuable Physical IntelligenceTM data and enabling advanced Artificial Intelligence solutions, leading to improved patient outcomes while reducing the cost, complexity and invasiveness of cardiac procedures.

Utah Tech Buzz highlighted the launch in a recent article.